Diabetic retinopathy: Vascular and inflammatory disease

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Semeraro, F ^a   Cancarini, A ^a   Dell'Omo, R ^b   Rezzola, S ^a   Romano, M R ^c   Costagliola, C ^b,d  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CHEMOKINE; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBROBLAST GROWTH FACTOR 2; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH FACTOR; HIGH MOBILITY GROUP B1 PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR; PROSTAGLANDIN F; SCATTER FACTOR; SCLEROPROTEIN; SOMATOMEDIN C; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; TENASCIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ADHESION PROTEIN 1; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; GLUCOSE BLOOD LEVEL;

ANGIOGENESIS; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; HYPOXEMIA; IMMUNE DYSREGULATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE; VITREOUS BODY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOXIA; IMMUNOLOGY; INFLAMMATION; METABOLISM; MITOCHONDRION; OXIDATIVE STRESS; RETINA; RETINA BLOOD VESSEL;

BLOOD GLUCOSE; CYTOKINES; DIABETIC RETINOPATHY; HUMANS; HYPOXIA; INFLAMMATION; MITOCHONDRIA; OXIDATIVE STRESS; RETINA; RETINAL VESSELS;

EID: 84934910272     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/582060     Document Type: Review

References (194)

1. Diabetes Atlas, 5th edition, 2014, http://www. idf. org/diabetesatlas.
2. M. Barot, M. R. Gokulgandhi, S. Patel, and A. K. Mitra, "Microvascular complications and diabetic retinopathy: recent advances and future implications, " Future Medicinal Chemistry, vol. 5, no. 3, pp. 301-314, 2013.
3. J. T. Durham and I. M. Herman, "Microvascular modifications in diabetic retinopathy, " Current Diabetes Reports, vol. 11, no. 4, pp. 253-264, 2011.
4. E. Beltramo and M. Porta, "Pericyte loss in diabetic retinopathy: mechanisms and consequences, " Current Medicinal Chemistry, vol. 20, no. 26, pp. 3218-3225, 2013.
5. R. B. Goldberg, "Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications, " Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 9, pp. 3171-3182, 2009.
6. R. Dell'Omo, F. Semeraro, G. Bamonte, F. Cifariello, M. R. Romano, and C. Costagliola, "Vitreous mediators in retinal hypoxic diseases, " Mediators of Inflammation, vol. 2013, Article ID935301, 16 pages, 2013.
7. H. Sone, Y. Kawakami, Y. Okuda et al. , "Vascular endothelial growth factor is induced by long-term high glucose concentration and up-regulated by acute glucose deprivation in cultured bovine retinal pigmented epithelial cells, " Biochemical and Biophysical Research Communications, vol. 221, no. 1, pp. 193-198, 1996.
8. C. Costagliola, "Oxidative state of glutathione in red blood cells and plasma of diabetic patients: in vivo and in vitro study, " Clinical Physiology and Biochemistry, vol. 8, no. 4, pp. 204-210, 1990.
9. T. P. Ellis, R. H. Choudhury, K. Kaul et al. , "Diabetic retinopathy and atherosclerosis: is there a link" Current Diabetes Reviews, vol. 9, no. 2, pp. 146-160, 2013.
10. C. Costagliola, V. Romano, M. de Tollis et al. , "TNF-alpha levels in tears: a novel biomarker to assess the degree of diabetic retinopathy, " Mediators of Inflammation, vol. 2013, Article ID 629529, 6 pages, 2013.
11. F. Semeraro, A. Cancarini, F. Morescalchi et al. , "Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy, " Diabetes and Metabolism, vol. 40, pp. 445-451, 2014.
12. A. Cancarini, C. Costagliola, R. dell'Omo et al. , "Effect of intravitreal bevacizumab on serum, aqueous, and vitreous humor levels of erythropoietin in patients with proliferative diabetic retinopathy, "Minerva Endocrinologica, vol. 39, pp. 305-311, 2014.
13. C. Costagliola, A. Daniele, R. dell'Omo et al. , "Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection, " Experimental Eye Research, vol. 110, pp. 50-54, 2013.
14. J. M. Tarr, K. Kaul, M. Chopra, E. M. Kohner, and R. Chibber, "Pathophysiology of diabetic retinopathy, " ISRN Ophthalmology, vol. 2013, Article ID 343560, 13 pages, 2013.
15. S. F. Abcouwer, "Angiogenic factors and cytokines in diabetic retinopathy, " Journal of Clinical & Cellular Immunology, vol. 11, pp. 1-12, 2013.
16. J. Tang and T. S. Kern, "Inflammation in diabetic retinopathy, " Progress in Retinal and Eye Research, vol. 30, no. 5, pp. 343-358, 2011.
17. J. I. Patel, G. M. Saleh, P. G. Hykin, Z. J. Gregor, and I. A. Cree, "Concentration of haemodynamic and inflammatory related cytokines in diabetic retinopathy, " Eye, vol. 22, no. 2, pp. 223-228, 2008.
18. C. Hernàndez, R. M. Segura, A. Fonollosa, E. Carrasco, G. Francisco, and R. Simo, "Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy, " Diabetic Medicine, vol. 22, no. 6, pp. 719-722, 2005.
19. H. Funatsu, H. Yamashita, H. Noma et al. , "Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients, " Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 243, no. 1, pp. 3-8, 2005.
20. P. Murugeswari, D. Shukla, A. Rajendran, R. Kim, P. Namperumalsamy, and V. Muthukkaruppan, "Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease, " Retina, vol. 28, no. 6, pp. 817-824, 2008.
21. O. Simo-Servat, C. Hernandez, and R. Simo, "Usefulness of the vitreous fluid analysis in the translational research of diabetic retinopathy, " Mediators of Inflammation, vol. 2012, Article ID 872978, 11 pages, 2012.
22. M. Dal Monte, S. Rezzola, M. Cammalleri et al. , "Antiangiogenic effectiveness of the urokinase receptor-derived peptide UPARANT in a model of oxygen induced retinopathy, " Investigative Ophthalmology & Visual Science, 2015.
23. S. Rezzola, M. D. Monte, M. Belleri et al. , "Therapeutic potential of anti-angiogenicmulti-targetN, O-sulfated E. Coli K5 polysaccharide in diabetic retinopathy, " Diabetes, 2015.
24. M. Brownlee, "Biochemistry and molecular cell biology of diabetic complications, " Nature, vol. 414, no. 6865, pp. 813-820, 2001.
25. D. Gologorsky, A. Thanos, and D. Vavvas, "Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy, " Mediators of Inflammation, vol. 2012, Article ID 629452, 10 pages, 2012.
26. K. Esposito, F. Nappo, R. Marfella et al. , "Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress, " Circulation, vol. 106, no. 16, pp. 2067-2072, 2002.
27. S. K. Lim and S. H. Park, "High glucose stimulates the expression of erythropoietin in rat glomerular epithelial cells, " Laboratory Animal Research, vol. 27, no. 3, pp. 245-250, 2011.
28. S. Yoshida, A. Yoshida, and T. Ishibashi, "Induction of IL-8, MPC-1, and bFGF by TNF-in retinal glial cells: implications for retinal neovascularization during post-ischemic inflammation, " Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 242, no. 5, pp. 409-413, 2004.
29. R. B. Caldwell, M. Bartoli, M. A. Behzadian et al. , "Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives, " Diabetes/Metabolism Research and Reviews, vol. 19, no. 6, pp. 442-455, 2003.
30. Z. A. Khan and S. Chakrabarti, "Growth factors in proliferative diabetic retinopathy, " Experimental Diabesity Research, vol. 4, no. 4, pp. 287-301, 2003.
31. F. Semeraro, A. Cancarini, E. Forbice et al. , "Erythropoietin and diabetic retinopathy, " Journal of Diabetes & Metabolism, vol. 4, article 2, 2013.
32. A. Zijlstra, M. Seandel, T. A. Kupriyanova et al. , "Proangiogenic role of neutrophil-like inflammatory heterophils during neovascularization induced by growth factors and human tumor cells, " Blood, vol. 107, no. 1, pp. 317-327, 2006.
33. K. Newton and V. M. Dixit, "Signaling in innate immunity and inflammation, " Cold Spring Harbor Perspectives in Biology, vol. 4, no. 3, 2012.
34. C. L. Speyer and P. A. Ward, "Role of endothelial chemokines and their receptors during inflammation, " Journal of Investigative Surgery, vol. 24, no. 1, pp. 18-27, 2011.
35. A. H. Sprague and R. A. Khalil, "Inflammatory cytokines in vascular dysfunction and vascular disease, " Biochemical Pharmacology, vol. 78, no. 6, pp. 539-552, 2009.
36. C. S. Williams, M. Mann, and R. N. DuBois, "The role of cyclooxygenases in inflammation, cancer, and development, " Oncogene, vol. 18, no. 55, pp. 7908-7916, 1999.
37. P. Romagnani, L. Lasagni, F. Annunziato, M. Serio, and S. Romagnani, "CXC chemokines: the regulatory link between inflammation and angiogenesis, " Trends in Immunology, vol. 25, no. 4, pp. 201-209, 2004.
38. E. Voronov, D. S. Shouval, Y. Krelin et al. , "IL-1 is required for tumor invasiveness and angiogenesis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 5, pp. 2645-2650, 2003.
39. A. Naldini, D. Leali, A. Pucci et al. , "Cutting edge: IL-1 mediates the proangiogenic activity of osteopontin-activated human monocytes, " Journal of Immunology, vol. 177, no. 7, pp. 4267-4270, 2006.
40. D. Leali, P. Dell'Era, H. Stabile et al. , "Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis, " The Journal of Immunology, vol. 171, no. 2, pp. 1085-1093, 2003.
41. A. C. Aplin, M. Gelati, E. Fogel, E. Carnevale, and R. F. Nicosia, "Angiopoietin-1 and vascular endothelial growth factor induce expression of inflammatory cytokines before angiogenesis, " Physiological Genomics, vol. 27, no. 1, pp. 20-28, 2006.
42. L. S. Angelo and R. Kurzrock, "Vascular endothelial growth factor and its relationship to inflammatory mediators, " Clinical Cancer Research, vol. 13, no. 10, pp. 2825-2830, 2007.
43. L. Zheng, S. J. Howell, D. A. Hatala, K. Huang, and T. S. Kern, "Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy, " Diabetes, vol. 56, pp. 337-345, 2007.
44. N. K. Agrawal, "Targeting inflammation in diabetes: newer therapeutic options, " World Journal of Diabetes, vol. 5, no. 5, pp. 697-710, 2014.
45. A. P. Adamis, "Is diabetic retinopathy an inflammatory disease" British Journal of Ophthalmology, vol. 86, no. 4, pp. 363-365, 2002.
46. S. Ishida, T. Usui, K. Yamashiro et al. , "VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization, " Journal of Experimental Medicine, vol. 198, no. 3, pp. 483-489, 2003.
47. T. Cheng, W. Cao, R. Wen, R. H. Steinberg, and M. M. LaVail, "Prostaglandin E2 induces vascular endothelial growth factor andbasicfibroblast growth factormRNAexpression in cultured ratMuller cells, " InvestigativeOphthalmologyandVisual Science, vol. 39, no. 3, pp. 581-591, 1998.
48. N. Bhagat, R. A. Grigorian, A. Tutela, and M. A. Zarbin, "Diabetic macular edema: pathogenesis and treatment, " Survey of Ophthalmology, vol. 54, no. 1, pp. 1-32, 2009.
49. T. C. Moore, J. E. Moore, Y. Kaji et al. , "The role of advanced glycation end products in retinal microvascular leukostasis, " Investigative Ophthalmology & Visual Science, vol. 44, no. 10, pp. 4457-4464, 2003.
50. A. M. Joussen, V. Poulaki, M. L. Le et al. , "A central role for inflammation in the pathogenesis of diabetic retinopathy, " FASEB Journal, vol. 18, no. 12, pp. 1450-1452, 2004.
51. Y. Kaji, T. Usui, S. Ishida et al. , "Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products, " Investigative Ophthalmology and Visual Science, vol. 48, no. 2, pp. 858-865, 2007.
52. X. Zhang, H. Zeng, S. Bao, N. Wang, and M. C. Gillies, "Diabetic macular edema: new concepts in patho-physiology and treatment, " Cell & Bioscience, vol. 4, article 27, 2014.
53. H. Noma, T. Mimura, K. Yasuda, and M. Shimura, "Role of inflammation in diabetic macular edema, " Ophthalmologica, vol. 232, no. 3, pp. 127-135, 2014.
54. Y. Mitamura, C. Harada, and T. Harada, "Role of cytokines and trophic factors in the pathogenesis of diabetic retinopathy, " Current Diabetes Reviews, vol. 1, no. 1, pp. 73-81, 2005.
55. F. Morescalchi, S. Duse, E. Gambicorti, M. R. Romano, C. Costagliola, and F. Semeraro, "Proliferative vitreoretinopathy after eye injuries: an overexpression of growth factors and cytokines leading to a retinal keloid, " Mediators of Inflammation, vol. 2013, Article ID 269787, 12 pages, 2013.
56. M. Bry, R. Kivela, V. M. Leppanev, and K. Alitao, "Vascular endothelial growth factor-B in physiology and disease, " Physiological Reviews, vol. 94, pp. 779-794, 2014.
57. H. Takahashi and M. Shibuya, "The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions, " Clinical Science, vol. 109, no. 3, pp. 227-241, 2005.
58. S. Hiratsuka, Y. Kataoka, K. Nakao et al. , "Vascular endothelial growth factor A (VEGF-A) is involved in guidance of VEGF receptor-positive cells to the anterior portion of early embryos, " Molecular and Cellular Biology, vol. 25, no. 1, pp. 355-363, 2005.
59. Y. Sakurai, K. Ohgimoto, Y. Kataoka, N. Yoshida, and M. Shibuya, "Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 4, pp. 1076-1081, 2005.
60. P. Carmeliet, L. Moons, A. Luttun et al. , "Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions, " Nature Medicine, vol. 7, no. 5, pp. 575-583, 2001.
61. R. O. Dull, J. Yuan, Y. S. Chang, J. Tarbell, R. K. Jain, and L. L. Munn, "Kinetics of placenta growth factor/vascular endothelial growth factor synergy in endothelial hydraulic conductivity and proliferation, " Microvascular Research, vol. 61, no. 2, pp. 203-210, 2001.
62. A. P. Levy, N. S. Levy, S. Wegner, and M. A. Goldberg, "Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia, " The Journal of Biological Chemistry, vol. 270, no. 22, pp. 13333-13340, 1995.
63. I. Stein, M. Neeman, D. Shweiki, A. Itin, and E. Keshet, "Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes, " Molecular and Cellular Biology, vol. 15, no. 10, pp. 5363-5368, 1995.
64. R. J. Melder, G. C. Koenig, B. P. Witwer, N. Safabakhsh, L. L. Munn, and R. K. Jain, "During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium, " Nature Medicine, vol. 2, no. 9, pp. 992-997, 1996.
65. J. Wang, E. Xu, M. H. Elliott, M. Zhu, and Y.-Z. Le, "Muller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage, " Diabetes, vol. 59, no. 9, pp. 2297-2305, 2010.
66. A. C. Clermont, L. P. Aiello, F. Mori, L. M. Aiello, and S.-E. Bursell, "Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy, " American Journal of Ophthalmology, vol. 124, no. 4, pp. 433-446, 1997.
67. A. P. Adamis, J. W. Miller, M.-T. Bernal et al. , "Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy, " American Journal of Ophthalmology, vol. 118, no. 4, pp. 445-450, 1994.
68. N. Matsunaga, Y. Chikaraishi, H. Izuta et al. , "Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy, " Ophthalmology, vol. 115, no. 11, pp. 1916-1922, 2008.
69. J. S. Penn, A. Madan, R. B. Caldwell, M. Bartoli, R. W. Caldwell, and M. E. Hartnett, "Vascular endothelial growth factor in eye disease, " Progress in Retinal and Eye Research, vol. 27, no. 4, pp. 331-371, 2008.
70. A. L. Angiolillo, C. Sgadari, D. D. Taub et al. , "Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo, "The Journal of Experimental Medicine, vol. 182, no. 1, pp. 155-162, 1995.
71. L. P. Aiello, R. L. Avery, P. G. Arrigg et al. , "Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders, " The New England Journal of Medicine, vol. 331, no. 22, pp. 1480-1487, 1994.
72. K. Shinoda, S. Ishida, S. Kawashima et al. , "Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus, " British Journal of Ophthalmology, vol. 83, no. 7, pp. 834-837, 1999.
73. E. Duh and L. P. Aiello, "Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox, " Diabetes, vol. 48, no. 10, pp. 1899-1906, 1999.
74. Y. Mitamura, A. Tashimo, Y. Nakamura et al. , "Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy, " Diabetes care, vol. 25, article 2352, 2002.
75. Y.-S. Chen, S. F. Hackett, C.-L. Schoenfeld, M. A. Vinores, S. A. Vinores, and P. A. Campochiaro, "Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes, " British Journal of Ophthalmology, vol. 81, no. 10, pp. 919-926, 1997.
76. M. Ziche, D. Maglione, D. Ribatti et al. , "Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic, " Laboratory Investigation, vol. 76, no. 4, pp. 517-531, 1997.
77. K. S. Spirin, M. Saghizadeh, S. L. Lewin, L. Zardi, M. C. Kenney, and A. V. Ljubimov, "Basement membrane and growth factor gene expression in normal and diabetic human retinas, " Current Eye Research, vol. 18, no. 6, pp. 490-499, 1999.
78. A. Khaliq, D. Foreman, A. Ahmed et al. , "Increased expression of placenta growth factor in proliferative diabetic retinopathy, " Laboratory Investigation, vol. 78, no. 1, pp. 109-116, 1998.
79. R. Chiquet-Ehrismann, E. J. Mackie, C. A. Pearson, and T. Sakakura, "Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis, " Cell, vol. 47, no. 1, pp. 131-139, 1986.
80. A. E. Canfield and A. M. Schor, "Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells, " Journal of Cell Science, vol. 108, no. 2, pp. 797-809, 1995.
81. Y. Mitamura, S. Takeuchi, K. Ohtsuka, A. Matsuda, N. Hiraiwa, andM. Kusakabe, "Tenascin-C levels in the vitreous of patients with proliferative diabetic retinopathy, " Diabetes Care, vol. 25, article 1899, 2002.
82. I. Immonen, K. Tervo, I. Virtanen, L. Laatikainen, and T. Tervo, "Immunohistochemical demonstration of cellular fibronectin and tenascin in human epiretinal membranes, " Acta Ophthalmologica, vol. 69, no. 4, pp. 466-471, 1991.
83. M. Hagedorn, P. Esser, P. Wiedemann, and K. Heimann, "Tenascin and decorin in epiretinal membranes of proliferative vitreoretinopathy and proliferative diabetic retinopathy, " German Journal of Ophthalmology, vol. 2, no. 1, pp. 28-31, 1993.
84. R. Burgos, C. Mateo, A. Canton, C. Hernandez, J. Mesa, and R. Simo, "Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a casecontrol study, " Diabetes Care, vol. 23, no. 1, pp. 80-83, 2000.
85. V. Poulaki, A. M. Joussen, N. Mitsiades, C. S. Mitsiades, E. F. Iliaki, and A. P. Adamis, "Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy, " American Journal of Pathology, vol. 165, no. 2, pp. 457-469, 2004.
86. M. Boulton, Z. Gregor, D. McLeod et al. , "Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management, " British Journal of Ophthalmology, vol. 81, no. 3, pp. 228-233, 1997.
87. B. M. Glaser, P. A. D'Amore, R. G. Michels, A. Patz, and A. Fenselau, "Demonstration of vasoproliferative activity from mammalian retina, " Journal of Cell Biology, vol. 84, no. 2, pp. 298-304, 1980.
88. C. G. Wong, K. A. Rich, L.-H. L. Liaw, H. T. Hsu, and M. W. Berns, "Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit, " Current Eye Research, vol. 22, no. 2, pp. 140-147, 2001.
89. A. Sivalingam, J. Kenney, G. C. Brown, W. E. Benson, and L. Donoso, "Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy, " Archives of Ophthalmology, vol. 108, no. 6, pp. 869-872, 1990.
90. A. Hueber, P. Wiedemann, P. Esser, and K. Heimann, "Basic fibroblast growth factormRNA, bFgF peptide and FGF receptor in epiretinal membranes of intraocular proliferative disorders (PVR and PDR), " International Ophthalmology, vol. 20, no. 6, pp. 345-350, 1996-1997.
91. M. Hollborn, C. Krausse, I. Iandiev et al. , "Glial cell expression of hepatocyte growth factor in vitreoretinal proliferative disease, " Laboratory Investigation, vol. 84, no. 8, pp. 963-972, 2004.
92. C. Harada, T. Harada, H.-M. A. Quah et al. , "Potential role of glial cell line-derived neurotrophic factor receptors in Muller glial cells during light-induced retinal degeneration, " Neuroscience, vol. 122, no. 1, pp. 229-235, 2003.
93. G. T. Stavri, I. C. Zachary, P. A. Baskerville, J. F. Martin, and J. D. Erusalimsky, "Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia, " Circulation, vol. 92, no. 1, pp. 11-14, 1995.
94. K. Matsumoto and T. Nakamura, "Emerging multipotent aspects of hepatocyte growth factor, " Journal of Biochemistry, vol. 119, no. 4, pp. 591-600, 1996.
95. A. Canton, R. Burgos, C. Hernandez et al. , "Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy, " British Journal of Ophthalmology, vol. 84, no. 7, pp. 732-735, 2000.
96. W. Cai, S. L. Rook, Z. Y. Jiang, N. Takahara, and L. P. Aiello, "Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth, " Investigative Ophthalmology and Visual Science, vol. 41, no. 7, pp. 1885-1893, 2000.
97. I. E. Blom, R. Goldschmeding, and A. Leask, "Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy" Matrix Biology, vol. 21, no. 6, pp. 473-482, 2002.
98. T. Kita, Y. Hata, M. Miura, S. Kawahara, S. Nakao, and T. Ishibashi, "Functional characteristics of connective tissue growth factor on vitreoretinal cells, " Diabetes, vol. 56, no. 5, pp. 1421-1428, 2007.
99. D. J. Kelly, Y. Zhang, R. M. Gow, S. Itescu, and R. E. Gilbert, "Cells expressing the stem cell factor receptor, c-kit, contribute to neoangiogenesis in diabetes, " Diabetes and Vascular Disease Research, vol. 2, no. 2, pp. 76-80, 2005.
100. A. J. Erslev, "Erythropoietin, " The New England Journal of Medicine, vol. 324, no. 19, pp. 1339-1344, 1991.
101. D. Watanabe, K. Suzuma, S. Matsui et al. , "Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy, " The New England Journal of Medicine, vol. 353, no. 8, pp. 782-792, 2005.
102. J. Chen, K. M. Connor, C. M. Aderman, and L. E. H. Smith, "Erythropoietin deficiency decreases vascular stability in mice, " Journal of Clinical Investigation, vol. 118, no. 2, pp. 526-533, 2008.
103. M. Garca-Ramrez, C. Hernandez, and R. Simo, "Expression of erythropoietin and its receptor in the human retina: a comparative study of diabetic and non-diabetic subjects, " Diabetes Care, vol. 31, no. 6, pp. 1189-1194, 2008.
104. K. Jaquet, K. Krause, M. Tawakol-Khodai, S. Geidel, and K.-H. Kuck, "Erythropoietin and VEGF exhibit equal angiogenic potential, " Microvascular Research, vol. 64, no. 2, pp. 326-333, 2002.
105. D. Ribatti, M. Presta, A. Vacca et al. , "Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo, " Blood, vol. 93, no. 8, pp. 2627-2636, 1999.
106. S. P. Becerra and J. Amaral, "Erythropoietin-an endogenous retinal survival factor, " The New England Journal of Medicine, vol. 347, no. 24, pp. 1968-1970, 2002.
107. Z. Z. Chong, J.-Q. Kang, and K. Maiese, "Erythropoietin is a novel vascular protectant through activation of AKt1 and mitochondrial modulation of cysteine proteases, " Circulation, vol. 106, no. 23, pp. 2973-2979, 2002.
108. M. Digicaylioglu and S. A. Lipton, "Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-B signalling cascades, " Nature, vol. 412, no. 6847, pp. 641-647, 2001.
109. C. Hernandez, A. Fonollosa, M. Garca-Ramrez et al. , "Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema, " Diabetes Care, vol. 29, no. 9, pp. 2028-2033, 2006.
110. Y. Katsura, T. Okano, K. Matsuno et al. , "Erythropoietin is highly elevated in vitreous fluid of patients with proliferative diabetic retinopathy, " Diabetes Care, vol. 28, no. 9, pp. 2252-2254, 2005.
111. G. L. Semenza, "Regulation of erythropoietin production. New insights into molecular mechanism of oxygen homeostasis, " Hematology/Oncology Clinics of North America, vol. 8, no. 5, pp. 863-884, 1994.
112. A. Stahl, A. Buchwald, G. Martinet al. , "Vitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema, " Retina, vol. 30, no. 9, pp. 1524-1529, 2010.
113. J. W. Fisher, "Landmark advances in the development of erythropoietin, " Experimental Biology and Medicine, vol. 235, no. 12, pp. 1398-1411, 2010.
114. N. Sekiguchi, T. Inoguchi, K. Kobayashi, N. Sonoda, and H. Nawata, "Erythropoietin attenuated high glucose-induced apoptosis in cultured human aortic endothelial cells, " Biochemical and Biophysical Research Communications, vol. 334, no. 1, pp. 218-222, 2005.
115. M. B. Grant, M. E. Boulton, and A. V. Ljubimov, "Erythropoietin: when liability becomes asset in neurovascular repair, " Journal of Clinical Investigation, vol. 118, no. 2, pp. 467-470, 2008.
116. H. Takagi, D. Watanabe, K. Suzuma et al. , "Novel role of erythropoietin in proliferative diabetic retinopathy, " Diabetes Research and Clinical Practice, vol. 77, no. 3, pp. S62-S64, 2007.
117. N. Kubota, Y. Terauchi, T. Yamauchi et al. , "Disruption of adiponectin causes insulin resistance and neointimal formation, " Journal of Biological Chemistry, vol. 277, no. 29, pp. 25863-25866, 2002.
118. J. Frystyk, L. Tarnow, T. Krarup Hansen, H.-H. Parving, and A. Flyvbjerg, "Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications, " Diabetologia, vol. 48, no. 9, pp. 1911-1918, 2005.
119. B. J. Goldstein and R. Scalia, "Adiponectin: a novel adipokine linking adipocytes and vascular function, " Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2563-2568, 2004.
120. M. I. Yilmaz, A. Sonmez, C. Acikel et al. , "Adiponectinmay play a part in the pathogenesis of diabetic retinopathy, " European Journal of Endocrinology, vol. 151, no. 1, pp. 135-140, 2004.
121. T. Cohen, D. Nahari, L. W. Cerem, G. Neufeld, and B.-Z. Levin, "Interleukin 6 induces the expression of vascular endothelial growth factor, " The Journal of Biological Chemistry, vol. 271, no. 2, pp. 736-741, 1996.
122. M. Morohoshi, K. Fujisawa, I. Uchimura, and F. Numano, "Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro, " Diabetes, vol. 45, no. 3, pp. 954-959, 1996.
123. F. Legendre, P. Bogdanowicz, K. Boumediene, and J. P. Pujol, "Role of interleukin 6 (IL6)/IL-6R-induced signal transducesrs and activators of transcription and mitogen-activaded protein kinase/extracellular, " The Journal of Rheumatology, vol. 32, pp. 1307-1316, 2005.
124. C. Symeonidis, E. Papakonstantinou, S. Androudi et al. , "Interleukin-6 and thematrixmetalloproteinase response in the vitreous during proliferative vitreoretinopathy, " Cytokine, vol. 54, no. 2, pp. 212-217, 2011.
125. D. D. Taub, M. Anver, J. J. Oppenheim, D. L. Longo, and W. J. Murphy, "T lymphocyte recruitment by interleukin-8 (IL-8): IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo, " Journal of Clinical Investigation, vol. 97, no. 8, pp. 1931-1941, 1996.
126. H. Ghasemi, T. Ghazanfari, R. Yaraee, S. Faghihzadeh, and Z. M. Hassan, "Roles of IL-8 in ocular inflammations: a review, " Ocular Immunology and Inflammation, vol. 19, no. 6, pp. 401-412, 2011.
127. M. C. Mocan, S. Kadayifcilar, and B. Eldem, "Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic retinopathy, " Canadian Journal of Ophthalmology, vol. 41, no. 6, pp. 747-752, 2006.
128. G. A. Limb, B. C. Little, A. Meager et al. , "Cytokines in proliferative vitreoretinopathy, " Eye, vol. 5, pp. 686-693, 1991.
129. C. Gustavsson, C.-D. Agardh, P. Hagert, andE. Agardh, "Inflammatory markers in nondiabetic and diabetic rat retinas exposed to ischemia followed by reperfusion, " Retina, vol. 28, no. 4, pp. 645-652, 2008.
130. O. Arjamaa, M. Pollonen, K. Kinnunen, T. Ryhanen, and K. Kaarniranta, "Increased IL-6 levels are not related to NF-B or HIF-1 transcription factors activity in the vitreous of proliferative diabetic retinopathy, " Journal of Diabetes and its Complications, vol. 25, no. 6, pp. 393-397, 2011.
131. I. K. Oh, S.-W. Kim, J. Oh, T. S. Lee, and K. Huh, "Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy, " Current Eye Research, vol. 35, no. 12, pp. 1116-1127, 2010.
132. G. Guarda and A. So, "Regulation of inflammasome activity, " Immunology, vol. 130, no. 3, pp. 329-336, 2010.
133. S. G. Elner, V. M. Elner, G. J. Jaffe, A. Stuart, S. L. Kunkel, and R. M. Strieter, "Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy, " Current Eye Research, vol. 14, no. 11, pp. 1045-1053, 1995.
134. J. T. Rosenbaum, J. R. Samples, S. H. Hefeneider, and E. L. Howes, "Ocular inflammatory effects of intravitreal interleukin 1, " Archives of Ophthalmology, vol. 105, no. 8, pp. 1117-1120, 1987.
135. J. A. Vincent and S. Mohr, "Inhibition of caspase-1/interleukin-1 signaling prevents degeneration of retinal capillaries in diabetes and galactosemia, " Diabetes, vol. 56, no. 1, pp. 224-230, 2007.
136. R. A. Kowluru and S. Odenbach, "Role of interleukin-1 in the pathogenesis of diabetic retinopathy, " British Journal of Ophthalmology, vol. 88, no. 10, pp. 1343-1347, 2004.
137. N. Parameswaran and S. Patial, "Tumor necrosis factor-a signaling in macrophages, " Critical Reviews in Eukaryotic Gene Expression, vol. 20, no. 2, pp. 87-103, 2010.
138. G. Tezel and M. B. Wax, "Increased production of tumor necrosis factor-by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells, " Journal of Neuroscience, vol. 20, no. 23, pp. 8693-8700, 2000.
139. E. A. Carswell, L. J. Old, R. L. Kassel, S. Green, N. Fiore, and B. Williamson, "An endotoxin induced serum factor that cuases necrosis of tumors, " Proceedings of the National Academy of Sciences of the United States of America, vol. 72, no. 9, pp. 3666-3670, 1975.
140. C. A. Aveleira, C.-M. Lin, S. F. Abcouwer, A. F. Ambrosio, and D. A. Antonetti, "TNF-signals through PKC/NF-B to alter the tight junction complex and increase retinal endothelial cell permeability, " Diabetes, vol. 59, no. 11, pp. 2872-2882, 2010.
141. M. G. Madigan, A. A. Sadun, N. S. Rao, P. U. Dugel, W. N. Tenhula, and P. S. Gill, "Tumor necrosis factor-alpha (TNF-)-induced optic neuropathy in rabbits, " Neurological Research, vol. 18, no. 2, pp. 176-184, 1996.
142. S. Majka, P. G. McGuire, and A. Das, "Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization, " Investigative Ophthalmology and Visual Science, vol. 43, no. 1, pp. 260-266, 2002.
143. S. E. Kahn, R. L. Hull, and K. M. Utzschneider, "Mechanisms linking obesity to insulin resistance and type 2 diabetes, " Nature, vol. 444, no. 7121, pp. 840-846, 2006.
144. S. Doganay, C. Evereklioglu, H. Er et al. , "Comparison of serum NO, TNF-, IL-1, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus, " Eye, vol. 16, no. 2, pp. 163-170, 2002.
145. Y. Behl, P. Krothapalli, T. Desta, A. DiPiazza, S. Roy, and D. T. Graves, "Diabetes-enhanced tumor necrosis factor-production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy, " The American Journal of Pathology, vol. 172, no. 5, pp. 1411-1418, 2008.
146. Y. Behl, P. Krothapalli, T. Desta, S. Roy, and D. T. Graves, "FOXO1 plays an important role in enhanced microvascular cell apoptosis and microvascular cell loss in type 1 and type 2 diabetic rats, " Diabetes, vol. 58, no. 4, pp. 917-925, 2009.
147. H. Huang, J. K. Gandhi, X. Zhong et al. , "TNF is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis, " Investigative Ophthalmology and Visual Science, vol. 52, no. 3, pp. 1336-1344, 2011.
148. M. T. Lotze andK. J. Tracey, "High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal, " Nature Reviews Immunology, vol. 5, no. 4, pp. 331-342, 2005.
149. N. Arimura, Y. Ki-I, T. Hashiguchi et al. , "Intraocular expression and release of high-mobility group box 1 protein in retinal detachment, " Laboratory Investigation, vol. 89, no. 3, pp. 278-289, 2009.
150. T. Watanabe, H. Keino, Y. Sato, A. Kudo, H. Kawakami, and A. A. Okada, "High mobility group box protein-1 in experimental autoimmune uveoretinitis, " Investigative Ophthalmology & Visual Science, vol. 50, no. 5, pp. 2283-2290, 2009.
151. S. Yang, K. Hirooka, Y. Liu et al. , "Deleterious role of anti-high mobility group box 1 monoclonal antibody in retinal ischemiareperfusion injury, " Current Eye Research, vol. 36, no. 11, pp. 1037-1046, 2011.
152. A. M. A. El-Asrar, M. I. Nawaz, D. Kangave et al. , "Highmobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy, " Molecular Vision, vol. 17, pp. 1829-1838, 2011.
153. J.-J. Lee, C.-C. Hsiao, I.-H. Yang et al. , "High-mobility group box 1 protein is implicated in advanced glycation end productsinduced vascular endothelial growth factor a production in the rat retinal ganglion cell line RGC-5, " Molecular Vision, vol. 18, pp. 838-850, 2012.
154. V. Jakus and N. Rietbrock, "Advanced glycation end-products and the progress of diabetic vascular complications, " Physiological Research, vol. 53, no. 2, pp. 131-142, 2004.
155. P. J. Barnes, "Nuclear factor-B, " International Journal of Biochemistry and Cell Biology, vol. 29, no. 6, pp. 867-870, 1997.
156. S. Kiechl, J. Wittmann, A. Giaccari et al. , "Blockade of receptor activator of nuclear factor-B (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus, " Nature Medicine, vol. 19, no. 3, pp. 358-363, 2013.
157. N. Sakai, H. L. van Sweringen, R. Schuster et al. , "Receptor activator of nuclear factor-B ligand (RANKL) protects against hepatic ischemia/reperfusion injury in mice, " Hepatology, vol. 55, no. 3, pp. 888-897, 2012.
158. G. L. Semenza, "Hydroxylation of HIF-1: oxygen sensing at the molecular level, " Physiology, vol. 19, no. 4, pp. 176-182, 2004.
159. O. Arjamaa and M. Nikinmaa, "Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors, " Experimental Eye Research, vol. 83, no. 3, pp. 473-483, 2006.
160. C. Treins, S. Giorgetti-Peraldi, J. Murdaca, M.-N. Monthouel-Kartmann, and E. van Obberghen, "Regulation of hypoxiainducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor I, " Molecular Endocrinology, vol. 19, no. 5, pp. 1304-1317, 2005.
161. V. Poulaki, W. Qin, A. M. Joussen et al. , "Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1 and VEGF, " The Journal of Clinical Investigation, vol. 109, no. 6, pp. 805-815, 2002.
162. A. M. A. El-Asrar, L. Missotten, and K. Geboes, "Expression of hypoxia-inducible factor-1 alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes, " British Journal of Ophthalmology, vol. 91, no. 6, pp. 822-826, 2007.
163. S. Frede, C. Stockmann, P. Freitag, and J. Fandrey, "Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-B, " Biochemical Journal, vol. 396, no. 3, pp. 517-527, 2006.
164. M. Gharaee-Kermani, E. M. Denholm, and S. H. Phan, "Costimulation of fibroblast collagen and transforming growth factor 1 gene expression by monocyte chemoattractant protein-1 via specific receptors, "The Journal of Biological Chemistry, vol. 271, no. 30, pp. 17779-17784, 1996.
165. K. H. Hong, J. Ryu, and K. H. Han, "Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A, " Blood, vol. 105, no. 4, pp. 1405-1407, 2005.
166. P. Esser, K. Heimann, and P. Wiedemann, "Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations, " British Journal of Ophthalmology, vol. 77, no. 11, pp. 731-733, 1993.
167. Y. Mitamura, S. Takeuchi, A. Matsuda, Y. Tagawa, Y. Mizue, and J. Nishihira, "Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy, " Ophthalmologica, vol. 215, no. 6, pp. 415-418, 2001.
168. A. Tashimo, Y. Mitamura, S. Nagai et al. , "Aqueous levels of macrophage migration inhibitory factor andmonocyte chemotactic protein-1 in patients with diabetic retinopathy, " Diabetic Medicine, vol. 21, no. 12, pp. 1292-1297, 2004.
169. W. Zhang, H. Liu, M. Al-Shabrawey, R. Caldwell, and R. Caldwell, "Inflammation and diabetic retinal microvascular complications, " Journal of Cardiovascular Disease Research, vol. 2, no. 2, pp. 96-103, 2011.
170. A. M. AbuEl-Asrar, S. Struyf, D. Kangave, K. Geboes, and J. Van Damme, "Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy, " European Cytokine Network, vol. 17, no. 3, pp. 155-165, 2006.
171. Y. Wakabayashi, Y. Usui, Y. Okunuki et al. , "Increased levels of monokine induced by interferon-gamma (Mig) in the vitreous of patients with diabetic retinopathy, " DiabeticMedicine, vol. 25, pp. 875-877, 2008.
172. R. Salcedo and J. J. Oppenheim, "Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses, "Microcirculation, vol. 10, no. 3-4, pp. 359-370, 2003.
173. J. M. Butler, S. M. Guthrie, M. Koc et al. , "SDF-1 is both necessary and sufficient to promote proliferative retinopathy, " Journal of Clinical Investigation, vol. 115, no. 1, pp. 86-93, 2005.
174. M. B. Grant, A. Afzal, P. Spoerri, H. Pan, L. C. Shaw, and R. N. Mames, "The role of growth factors in the pathogenesis of diabetic retinopathy, " Expert Opinion on Investigational Drugs, vol. 13, no. 10, pp. 1275-1293, 2004.
175. J.-J. You, C.-H. Yang, J.-S. Huang, M.-S. Chen, and C.-M. Yang, "Fractalkine, a CX3C chemokine, as a mediator of ocular angiogenesis, " Investigative Ophthalmology and Visual Science, vol. 48, no. 11, pp. 5290-5298, 2007.
176. L. Y. Chen, Y. H. Zhuo, Y. H. Li et al. , "Expression of stromal cell-derived factor-1 in diabetic retinopathy, " Chinese Medical Journal, vol. 123, no. 8, pp. 984-988, 2010.
177. Y. Mitamura, S. Takeuchi, A. Matsuda, Y. Tagawa, Y. Mizue, and J. Nishihira, "Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative diabetic retinopathy, " British Journal of Ophthalmology, vol. 84, no. 6, pp. 636-639, 2000.
178. M. Lu, V. L. Perez, N. Ma et al. , "VEGF increases retinal vascular ICAM-1 expression in vivo, " Investigative Ophthalmology and Visual Science, vol. 40, no. 8, pp. 1808-1812, 1999.
179. D. S. McLeod, D. J. Lefer, C. Merges, and G. A. Lutty, "Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid, " The American Journal of Pathology, vol. 147, no. 3, pp. 642-653, 1995.
180. F. C. Barouch, K. Miyamoto, J. R. Allport et al. , "Integrinmediated neutrophil adhesion and retinal leukostasis in diabetes, " Investigative Ophthalmology and Visual Science, vol. 41, no. 5, pp. 1153-1158, 2000.
181. C. Hernandez, R. Burgos, A. Canton, J. Garca-Arum, R. M. Segura, and R. Simo, "Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: a case-control study, " Diabetes Care, vol. 24, no. 3, pp. 516-521, 2001.
182. J. Adamiec-Mroczek, J. Oficjalska-Mynczak, and M. Misiuk-Hojo, "Roles of endothelin-1 and selected proinflammatory cytokines in the pathogenesis of proliferative diabetic retinopathy: analysis of vitreous samples, " Cytokine, vol. 49, no. 3, pp. 269-274, 2010.
183. M. Murata, K. Noda, J. Fukuhara et al. , "Soluble vascular adhesion protein-1 accumulates in proliferative diabetic retinopathy, " Investigative Ophthalmology and Visual Science, vol. 53, no. 7, pp. 4055-4062, 2012.
184. C. Baudouin, D. Fredj-Reygrobellet, F. Brignole, P. Lapalus, and P. Gastaud, "MHC class II antigen expression by ocular cells in proliferative diabetic retinopathy, " Fundamental and Clinical Pharmacology, vol. 7, no. 9, pp. 523-530, 1993.
185. B.-B. Gao, X. Chen, N. Timothy, L. P. Aiello, and E. P. Feener, "Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy, " Journal of Proteome Research, vol. 7, no. 6, pp. 2516-2525, 2008.
186. H. Zong, M. Ward, A. Madden et al. , "Hyperglycaemia-induced pro-inflammatory responses by retinalMuller glia are regulated by the receptor for advanced glycation end-products (RAGE), " Diabetologia, vol. 53, no. 12, pp. 2656-2666, 2010.
187. A. M. A. El-Asrar, L. Missotten, and K. Geboes, "Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes, " The British Journal of Ophthalmology, vol. 92, no. 11, pp. 1534-1539, 2008.
188. A. M. Joussen, V. Poulaki, N. Mitsiades et al. , "Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression, " The FASEB Journal, vol. 16, no. 3, pp. 438-440, 2002.
189. S. P. Ayalasomayajula and U. B. Kompella, "Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic ratmodel, " European Journal of Pharmacology, vol. 458, no. 3, pp. 283-289, 2003.
190. M. L. Schwartzman, P. Iserovich, K. Gotlinger et al. , "Profile of lipid and protein autacoids in diabetic vitreous correlates with the progression of diabetic retinopathy, " Diabetes, vol. 59, no. 7, pp. 1780-1788, 2010.
191. R. A. Gubitosi-Klug, R. Talahalli, Y. Du, J. L. Nadler, and T. S. Kern, "5-Lipoxygenase, but not 12/15-lipoxygenase, contributes to degeneration of retinal capillaries in a mouse model of diabetic retinopathy, " Diabetes, vol. 57, no. 5, pp. 1387-1393, 2008.
192. G. A. Lutty, D. S. McLeod, C. Merges, A. Diggs, and J. Plouet, "Localization of vascular endothelial growth factor in human retina and choroid, " Archives of Ophthalmology, vol. 114, no. 8, pp. 971-977, 1996.
193. Early Treatment Diabetic Retinopathy Study Research Group, "Effects of aspirin treatment on diabetic retionopathy. ETDRS report number 8, " Ophthalmology, vol. 98, pp. 757-777, 1991.
194. S. Nakao, M. Arima, K. Ishikawa et al. , "Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and reentry into the circulation in retinal angiogenesis, " Investigative Ophthalmology and Visual Science, vol. 53, no. 7, pp. 4323-4328, 2012.